ZLAB Latest Press Releases

-- October 23, 2026 --

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer Business Wire 6:33 AM

-- October 22, 2026 --

Zai Lab Announces $250 Million Private Placement Business Wire 8:52 PM

-- October 21, 2026 --

Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026 Business Wire 7:30 AM

-- October 14, 2026 --

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Ra Bispecific Antibody, for Atopic Diseases Business Wire 7:00 AM

-- September 29, 2026 --

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Business Wire 8:07 AM

-- August 17, 2026 --

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis Business Wire 6:00 AM

-- August 6, 2026 --

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates Business Wire 6:30 AM

-- August 3, 2026 --

U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs) Business Wire 7:00 AM

-- July 22, 2026 --

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026 Business Wire 7:30 AM

-- June 16, 2026 --

Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas Business Wire 7:00 AM

-- June 8, 2026 --

Zai Lab Receives China NMPA Approval of TIVDAK (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer Business Wire 8:34 PM

Market Data Delayed 15 Minutes